MIRMMirum Pharmaceuticals Inc

Mirum and Incyte's zilurgisertib cut new bone lesion formation in rare disease FOP, as the FDA begins Priority Review of the NDA with a Sept. 26, 2026, decision date.

Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (12 years of age) with...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 10,100 shares of common stock and 13,350...

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgisertib, an investigational ALK2 inhibitor, in patients with fibrodysplasia ossificans progressiva (FOP) will be presented at ENDO 2026, the...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking results from the Phase 2b VISTAS study of volixibat in PSC and Phase 2b AZURE-1 study of brelovitug in HDV, alongside data featuring its...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will present new data at the European Association for the Study of the Liver (EASL) International Liver Congress 2026, taking place May 27-30, 2026, in Barcelona, Spain. Presentations span Mirums...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on May 11, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 22,950 shares of common stock and 31,300...

Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible...